# Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.

> **NCT00420316** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1613 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Rotarix (primary vaccination study)
- **BIOLOGICAL:** Placebo (primary vaccination study)

## Key facts

- **NCT ID:** NCT00420316
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-12
- **Primary completion:** 2007-08-08
- **Final completion:** 2007-08-08
- **Target enrollment:** 1613 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420316, "Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00420316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*